<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83480">
  <stage>Registered</stage>
  <submitdate>28/01/2009</submitdate>
  <approvaldate>15/06/2009</approvaldate>
  <actrnumber>ACTRN12609000458235</actrnumber>
  <trial_identification>
    <studytitle>Study to evaluate if macitentan is efficient and safe enough to be used for treatment of idiopathic pulmonary fibrosis.</studytitle>
    <scientifictitle>A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis.</scientifictitle>
    <utrn />
    <trialacronym>MUSIC: Macitentan USe in an Idiopathic pulmonary fibrosis Clinical study</trialacronym>
    <secondaryid>NCT00903331</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Pulmonary Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Macitentan 10 mg, tablet. Taken orally, once daily, every morning throughout Period 1 (12 months) and Period 2 (variable, at least a further 12 months), until the last patient has completed 24 months therapy (Period 1 and 2 combined) unless the study medication is prematurely discontinued.</interventions>
    <comparator>Placebo (sugar pill) alone. Tablet taken orally, once daily, every morning throughout Period 1 (12 months) and Period 2 (variable, at least a further 12 months), until the last patient has completed 24 months therapy (Period 1 and 2 combined) unless the study medication is prematurely discontinued.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary efficacy endpoint: Change from baseline to End-of-Period 1 in Forced Vital Capacity (FVC) as measured by Pulmonary Function Tests (PFTs).
A mean difference from placebo of at least 0.1 liter is to be detected and is considered clinically meaningful. Patients with an at least stable FVC have a statistically significant survival benefit over those with a decrease in FVC [Noble 2006]. Thus, change in FVC at 1 year provides a reasonable basis for evaluating efficacy of a new treatment.</outcome>
      <timepoint>End-of-Period 1: occurs at 12 months after subject randomisation or earlier in case of premature discontinuation of study medication during Period 1.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary efficacy endpoint: Time to occurrence of disease worsening or death up to End-of-Study. Disease worsening is defined as worsening of Pulmonary Function Tests (PFTs) or acute respiratory decompensation of Idiopathic Pulmonary Fibrosis (IPF).</outcome>
      <timepoint>At End-of-Study, after the last patient randomised has completed at least 24 months therapy.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Signed informed consent.
- IPF diagnosis within 3 years prior to randomization, proven according to American Thoracic Society/European Respiratory Society (ATS/ERS) consensus conference criteria, with surgical lung biopsy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Interstitial lung disease due to conditions other than IPF.
- Presence of extensive honeycombing on baseline high resolution computed tomography (HRCT) scan performed within 3 months prior to randomization.
- Forced Vital Capacity (FVC) &lt; 50% predicted, or FVC &lt; 1.2 liter.
- Diffusing capacity of the lung for carbon monoxide (DLco) &lt; 30% predicted.
- Residual volume at least 120% predicted.
- Forced expiratory volume of the lung in 1 second (FEV1)/FVC &lt;0.70.
- Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) &gt; 1.5 x Upper limit of Normal (ULN). 
- Hemoglobin &lt; 75% of the lower limit of the normal range.
- Systolic Blood Pressure (sBP) &lt; 100 mmHg.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is done by a central randomisation system.</concealment>
    <sequence>Stratified allocation (stratification by site). Simple randomisation by using a randomisation table created by a computer software (i.e., computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>27/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>156</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4032</postcode>
    <postcode>6000</postcode>
    <postcode>2010</postcode>
    <postcode>3004</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Actelion Pharmaceuticals Australia Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Suite 6, 13 B Narabang Way, 
Belrose NSW 2085, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Actelion Pharmaceuticals Australia Pty Ltd</fundingname>
      <fundingaddress>Suite 6, 13 B Narabang Way, 
Belrose NSW 2085, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with an unknown cause. Outside of Japan, no drug has been approved so far for the treatment of IPF. 
The study medication that is tested in this research, macitentan, works by blocking the effect of a substance called endothelin, which has been detected in increased amounts in patients with IPF. By blocking the action of endothelin, macitentan may increase the breathing capacity, improve the quality of life of patients and reduce the progression of the disease. 
The main purpose of this study is to find out if macitentan is efficient and safe enough to be used for treatment of IPF.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>Room 4112 Level 4, Kirkman House, 10 Murray St, Royal Perth Hospital
Perth WA  6000</ethicaddress>
      <ethicapprovaldate>26/03/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>4/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Prince Charles Hospital Metro North Health Service District</ethicname>
      <ethicaddress>Rode Road 
CHERMSIDE QLD 4032</ethicaddress>
      <ethicapprovaldate>31/03/2009</ethicapprovaldate>
      <hrec>HREC/09/QPCH/7</hrec>
      <ethicsubmitdate>5/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office Level 6 de Lacey Building St. Vincent's Hospital 390 Victoria Street DARLINGHURST NSW 2010 Australia</ethicaddress>
      <ethicapprovaldate>21/04/2009</ethicapprovaldate>
      <hrec>HREC/09/SVH/20</hrec>
      <ethicsubmitdate>23/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Commitee</ethicname>
      <ethicaddress>Alfred Hospital,
Commercial Rd
Melbourne VIC 3004</ethicaddress>
      <ethicapprovaldate>24/06/2009</ethicapprovaldate>
      <hrec>148/09</hrec>
      <ethicsubmitdate>27/04/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Glen Pater</name>
      <address>Regional Medical Director
Actelion Pharmaceuticals Australia Pty Ltd
Suite 6, 13 B Narabang Way, 
Belrose NSW 2085, Australia</address>
      <phone>+612 94864600</phone>
      <fax>+612 99861344</fax>
      <email>glen.pater@actelion.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Tanya Robb</name>
      <address>Regional Monitor
Actelion Pharmaceuticals Australia Pty Ltd
Suite 6, 13 B Narabang Way, 
Belrose NSW 2085, Australia</address>
      <phone>+612 94864600</phone>
      <fax>+612 99861344</fax>
      <email>tanya.robb@actelion.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Tanya Robb</name>
      <address>Regional Monitor
Actelion Pharmaceuticals Australia Pty Ltd
Suite 6, 13 B Narabang Way, 
Belrose NSW 2085, Australia</address>
      <phone>+612 94864600</phone>
      <fax>+612 99861344</fax>
      <email>tanya.robb@actelion.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>